Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1984-06-26
1989-07-04
Rosen, Sam
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424101, A61K 3702
Patent
active
048450740
ABSTRACT:
The invention herein describes the heat treatment of lyophilized Factor VIII to rid it of viral infectiveness.
REFERENCES:
patent: 3041242 (1962-06-01), Barr et al.
patent: 3100737 (1963-08-01), Auerswald et al.
patent: 3859168 (1975-01-01), Barth et al.
patent: 4250139 (1981-02-01), Luck et al.
patent: 4297344 (1981-10-01), Schwinn et al.
patent: 4327086 (1982-04-01), Fukishima et al.
patent: 4347259 (1982-08-01), Suzuki et al.
patent: 4495278 (1985-01-01), Thomas
Kraft et al., "Lyophilization of Poliomyelitis Virus. Heat Inactivation of Dry MEFL Virus," Proc. Soc. Exp. Biol. Med., 9:306-309, (1953).
Spaet et al., Properties of Bovine Anti Hemophilic Factor, Bovine Anti Hemophilic Factor, (1953).
Bidwell, The Purification of Bovine Antihemophilic Globulin, Br. J. Hematol, 1:35-45, (1955).
MacFarlene et al., The Use of Animal Antihemophlin Globulin and Human Plasma in Thirteen Cases, Lancet, (1957).
Bertrand et al., "Clinical Investigations with a Heat-Treated Plasma Protein Fraction--Plasmanate," Vox Sang., 4385-402, (1959).
Baumgarten et al., Thrombosis Et Diathesis Haemorrhagica, vol. 9, p. 354, (1963).
Podolsky et al., Improved Method of Lyophilic Dessication of Glucose Stabilized Plasma, Problems of Hematology and Blood Transfusion, vol. 4, pp. 27-32, (1967).
Rosenberg et al., "Thermoinactivation of Virus of Botkin's Disease (Hepatite Virus) in Dry Fibrinogen and Albumin Preparations," XII International Congress on Blood Transfusion Abstracts, MIR Publishers, Moscow, 1969, pp. 473-475.
Brozovic et al., "Stability of Prothrombin and Factor VII in Freeze-Dried Plasma," J. Clin. Path., 24:690-693, (1971).
Rosenberg et al., "On the Thermoinactivation of Botkin's Hepatitis Virus in Dry Fibrinogen and Albumin Preparations", XII International Congress on Blood Transfusion Abstracts, Moscow, U.S.S.R., Aug. 17-23, 1969, Bibl. Haemat., No. 38, part II, pp. 474-478, (Karger, Basel 1971).
Bangham et al., "Stability of Some Clotting Factors in Freeze-Dried Factor VIII-Reference Plasma and Concentrate," Chem. Abstracts, 76:22760u, (1972).
Apostolov et al., "Selective Inactivation of the Infectivity of Freeze-Dried Sendai Virus by Heat," Cytobiology, 10:255-259, (1973).
Sirridge, Laboratory Evaluation of Hemostatis, Second Edition, Lea & Febiger, Philadelphia, 1974, pp. 7-8.
Funakoshi et al., "Injectable Inactivated Vaccine Against Hepatitis B," Chem. Abstracts, 89:65254t, (1978).
Schable et al., "Stability of a Reference Panel of Lyophilized Hepatitis B Antigens and Antibodies," J. Biol. Standardization, 7:293-299, (1979).
Thomas, Baxter-Travenol, pp. 1-6, 10/29/79.
Rosenberg et al., "Hemostatic Human Blood Fractions for Transfusion: Antihemophiliac Plasma, Antihemophiliac Globulin, and Fibrinogen," Problemy Gematologii i Perelivaniya Krovi, vol. 8, No. 6, p. 3, (1963).
D. R. Bangham et al., "Stability of Some Clotting Factors in Freeze-Dried Factor VIII-Reference Plasma and Concentrate," Hemophilia Research, Clinical and Psycho-Social Aspects, VI Congress of the World Federation of Hemophilia, ed. by Deutch et al., pp. 89-98, (1970).
G. M. Thelin, "Preparation and Standardization of a Stable AHF Plasma," Thromb Diathes. Haemmorh., vol. 19, pp. 423-429, (1968).
Aronson et al., "Historical and Future Therapeutic Plasma Derivatives (Epilogue)," Seminars in Thrombosis and Hemostasis, VI(2): 121-123, (1980).
Schwinn et al., "Blood Coagulation Factors," Chem. Abstracts, 94:36335t, (1981).
Rubinstein, XIV Congress of the World Federation of Hemophilia, San Jose, Costa Rica, Jul. 3-7, 1981, (Abstract FC-5).
Rubinstein, Thrombosis and Haemostasis, vol. 46, No. 1, p. 338, Jul. 12, 1981, (Abstract 1051).
Rubinstein, Thrombosis and Haemostasis, vol. 46, No. 1, p. 339, Jul. 12, 1981, (Abstract 1054).
Rubinstein, Blood, vol. 58, No. 5, Suppl. 1, Nov. 1981, (Abstract 650).
Rubinstein, XIV Congress of the World Federation of Haemophilia, San Jose, Costa Rica, Jul. 3-7, 1981, (Abstract FC-6).
Gerety et al., "Plasma Derivatives and Viral Hepatitis," Transfusion 22(5):347, (1982).
Tabor et al., Infectious Complications of Blood Transfusion, Academic Press, New York, 1982, pp. 6, 24.
Plasma Products: Use and Management, A Technical Workshop, Kolins et al., (eds.), The Committee on Technical Workshops, American Association of Blood Banks, Anaheim, Calif., (1982).
Colombo et al., The Lancet, Jul. 6, 1985, pp. 1-4.
Koefper et al., "Prevalence of Antibodies to AIDS-Associated Retrovirus . . . Recovery of Infectious Virus from Hemophiliacs in San Francisco," International Conference on AIDS, Jun. 23-25, 1986.
Jaffe et al., "Outcome of HTLV-III/LAV in a Cohort of Gay Men," NIH Consensus Development Conference, Jul. 7-9, 1986.
Goedert, "The Medical Consequences of HTLV-III Infection," NIH Consensus Development Conference, Jul. 7-9, 1986.
Cowdery et al., "Stability Characteristics of Freeze-Dried Human Live Virus Vaccines," Develop. Biol. Standard 36:297-303.
Cedars Sinai Medical Center
Rosen Sam
LandOfFree
Heat treatment of Factor VIII does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heat treatment of Factor VIII, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heat treatment of Factor VIII will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-852451